The actions and effects of ordopidine are similar to those of its close analoguepridopidine (which it differs from only by a single methyl group).[3] Subsequent to their initial characterization, pridopidine was found to act as a sigma receptorligand with much higher affinity than for the dopamine D2 receptor, with this balance of activities potentially explaining its atypicality and "dopaminergic stabilizer" properties.[5]
Ordopidine was first described in the scientific literature by 2009.[4] The drug was developed by Carlsson Research, NeuroSearch Sweden, and Saniona.[1][2] As of June 2019, no recent development has been reported.[1][2] Ordopidine has reached phase 1clinical trials.[1][2]
